Is Novartis a Good Stock to Buy Right Now?
Novartis (NYSE: NVS) is a company in transition. Now, Novartis is close to completing this long-winded transition with the upcoming spin-off of its generic drug business, Sandoz, later this year. With a debt-to-equity ratio of 47%, Novartis' balance sheet isn't overly levered, especially compared to many of its big pharma peers.